Dubrovska et al. found that the inhibition of PI3K/mTOR activity by BEZ235 led to a decrease in the population of CD133+/CD44+ prostate cancer progenitor cells in a mouse xenograft model [41]. This evidence concerns the gene CD44 and prostate cancer.